Research

Zacks Small Cap Research – CTSO: CytoSorbents Reports 4th quarter and 2024 Financial Results Which Showed Impressive Product Revenue Growth That Exceeded Our Expectations. – Go Health Pro

by

By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT Update on the DrugSorb-ATR Regulatory Process Management reiterated that their De Novo DrugSorb-ATR submission continued to be in interactive review with FDA, that their Medical Device License application to Health Canada was in advanced review, and that they continue to expect regulatory decisions in … Read more

Zacks Small Cap Research – SBC: Recent Growth Measures Include Multi-Brand Strategy, Revised Pricing / Fee Structures, New Service Offerings – Go Health Pro

by
Zacks Small Cap Research – SBC: Recent Growth Measures Include Multi-Brand Strategy, Revised Pricing / Fee Structures, New Service Offerings – Go Health Pro

By M. Marin NASDAQ:SBC READ THE FULL SBC RESEARCH REPORT Initiatives include multi-brand strategy, revising franchisee fee structure & strategic pricing to drive customer repeat visits SBC Medical Group Holdings (NASDAQ:SBC) which provides end-to-end solutions enabling aesthetics clinics to launch, expand and/or operate their businesses, maintained its growth strategy of adding franchise clinics throughout 2024. … Read more

Zacks Small Cap Research – LTRN: 2024 Financial Results – Go Health Pro

by
Zacks Small Cap Research – LTRN: 2024 Financial Results – Go Health Pro

By John Vandermosten, CFA NASDAQ:LTRN READ THE FULL LTRN RESEARCH REPORT Lantern Pharma, Inc (NASDAQ:LTRN) reports 2024 results highlighting several achievements including progress on its HARMONIC, LP-184 and LP-284 trials, a portfolio of expedited designations in multiple indications and advances in the RADR platform with modules that offer predictive algorithms for blood brain barrier (BBB) … Read more

Zacks Small Cap Research – IMNN: Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer… – Go Health Pro

by
Zacks Small Cap Research – IMNN: Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer… – Go Health Pro

By David Bautz, PhD NASDAQ:IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer On March 24, 2025, Imunon, Inc. (NASDAQ:IMNN) announced it reached alignment with the U.S. FDA on the protocol for a Phase 3 clinical trial, referred to as OVATION 3, of … Read more

Zacks Small Cap Research – VIOT: A deep value growth story delivers solid results. Increasing our estimates and valuation target to $4.50 – Go Health Pro

by

By Brian Lantier, CFA NASDAQ:VIOT READ THE FULL VIOT RESEARCH REPORT On Tuesday, March 25th, Viomi Technology (NASDAQ:VIOT) released its second half and full year for 2024. As a result of the company’s divestiture of its IoT business in August 2024, the company is a pure-play home water systems and home appliance company. Importantly, the … Read more